Market News & Trends
Cellaria Adds Next-Generation RNA Reprogramming & Stem Cell Services
Cellaria, LLC, a scientific innovator that develops revolutionary new cancer models for challenging tumors, recently announced the expansion of its offerings to include a suite…
MilliporeSigma Introduces Mobius® MyWay Portfolio for Customized Single-Use Assemblies
MilliporeSigma, a leader in single-use technology, recently launched an industry first - the Mobius® MyWay portfolio, a program that allows more flexibility, better supply predictability,…
Aptar Pharma Inaugurates Congers Site Expansion, Supports Growth in Three Directions
Aptar Pharma’s site expansion in Congers, NY, was inaugurated on March 20 by Stephan Tanda, AptarGroup’s President and CEO, Salim Haffar, President of Aptar Pharma,…
Neothetics Announces Last Subject Enrolled in Phase II Trial
Neothetics, Inc. recently announced completion of subject enrollment for its Phase II proof-of-concept trial, LIPO-202-CL-31, for the reduction of submental subcutaneous fat. “We are excited…
Second Study Validates Role in Recurrent Cardiac Events
Interleukin Genetics, Inc. recently announced the presentation of clinical data from “The Ioannina Study” at the 66th Annual Scientific Session & Expo of the American…
Cytokinetics Announces Additional Results From Phase II Trial
Cytokinetics, Inc. recently announced that additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase II trial…
Aptar Pharma's Preservative-Free Multidose Dispenser Chosen for the First Time
Aptar Pharma’s innovative and patented preservative-free multidose Ophthalmic Squeeze Dispenser is available for patients in the US prescription market for the first time with Allergan’s…
Aptar Pharma's Preservative-Free Multidose Dispenser Chosen for the First Time
Aptar Pharma’s innovative and patented preservative-free multidose Ophthalmic Squeeze Dispenser is available for patients in the US prescription market for the first time with Allergan’s…
Nemera Wins Editor's Choice Category at INTERPHEX Awards for Safelia®
International Pharmaceutical Expo (INTERPHEX), the premier event dedicated to pharmaceutical and biotechnology innovation, technology, and knowledge from development through commercialization and sponsored by the Parenteral…
Nemera Wins Editor's Choice Category at INTERPHEX Awards for Safelia®
International Pharmaceutical Expo (INTERPHEX), the premier event dedicated to pharmaceutical and biotechnology innovation, technology, and knowledge from development through commercialization and sponsored by the Parenteral…
Alcami Introduces Seamless Customer Experience With New Customer Portal & Application, Alcami OnDemand™
Alcami, a leading provider of custom development and manufacturing services for the pharmaceutical and biotechnology industries, is setting the industry standard for project management and…
Alcami Introduces Seamless Customer Experience With New Customer Portal & Application, Alcami OnDemand™
Alcami, a leading provider of custom development and manufacturing services for the pharmaceutical and biotechnology industries, is setting the industry standard for project management and…
Mucodel Pharma Announces Patent Allowance for Co-Gel Buccal Naloxone
Mucodel Pharma LLC recently announced it has received a notice of allowance from the United States Patent and Trademark Office for its utility patent application…
Vtesse Completes Enrollment of Phase IIb/III Pivotal Clinical Trial
Vtesse, Inc. recently announced its registrational study of investigational drug VTS-270 in Niemann-Pick Type C1 disease (NPC) is fully enrolled. "Completing enrollment in the pivotal…
SG Lab & Toxikon Europe Sign Partnership Agreement
Italian Stevanato Group, through its laboratory SG Lab, has signed a partnership agreement with Toxikon Europe, the Belgian Contract Research Organization (CRO) to include extractables…
Roquette Announces Commitment to Provide New Product Offerings
New product offerings are low endotoxin, multi-compendial-grade materials for cell culture and biologic drug formulations. These products extend Roquette's commitment to helping customers save and…
MRC Technology Licenses Antibody to Newsummit Biopharma
MRC Technology recently announced it has licensed an antibody to Newsummit Biopharma, a leading China-based drug development process solutions provider, for development of a novel…
Cell Design Labs Announces Issuance of Broad Patent for Programmable Car-T Cells
Cell Design Labs, Inc. recently announced the issuance of U.S. Patent No. 9,587,020, titled Chimeric Antigen Receptor and Methods of Use Thereof. This patent, issued…
TiGenix Receives Positive Feedback From the FDA on Global Phase III Trial Protocol
TiGenix NV, an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platform of allogeneic stem cells, recently announced it has…
ObsEva Begins Phase III Clinical Program
ObsEva SA, a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and…
